Resolution: standard / high
Figure 7.
Changes in plasma VEGF-A (ratio to baseline VEGF-A) according to clinical benefit
during the first two treatment cycles and at the time of later progression (for patients
that initially obtained a clinical benefit). CB: Clinical benefit; PD: Disease progression
Kontovinis et al. BMC Cancer 2009 9:82 doi:10.1186/1471-2407-9-82
Download authors' original image